| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 29, 2020
DUBLIN, May 29, 2020 (GLOBE NEWSWIRE) -- During this critical time, Medtronic remains committed to our strategy of delivering critical care products ― designed and indicated for Extracorporeal...
-
May 19, 2020
DUBLIN, May 19, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. launch of Kyphon Assist™ Directional Cannula for use with its...
-
May 18, 2020
DUBLIN, May 18, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced Jeffrey J. Popma, M.D., professor of medicine at Harvard Medical School...
-
May 15, 2020Milestone Results Presented as Late-Breaking Clinical Science at SCAI 2020
DUBLIN, May 15, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced results from two late-breaking clinical trials presented virtually at the 2020 Society for Cardiovascular...
-
May 8, 2020New Data Unveiled at Heart Rhythm 2020 Demonstrate Effectiveness of App-Based Remote Monitoring of Medtronic Cardiac Devices, Significant Reduction in Complications with Micra Leadless Pacemaker
DUBLIN, May 08, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced results from late-breaking clinical trials evaluating the MyCareLink Heart™ mobile app and the Micra®...
-
Mar 30, 2020First Study in the U.S. and Japan to Report Results on One-Month DAPT Duration in High Bleeding Risk Patients with Current-Generation DES
DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR)...
-
Mar 29, 2020ACC.20/WCC: Low Rates of Paravalvular Leak and High Survival Observed in Late-breaking Clinical Trial of Low-Risk Bicuspid Aortic Stenosis Patients
DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced late-breaking clinical data from the Low Risk Bicuspid Study assessing...
-
Mar 29, 2020ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication
DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial....
-
Feb 4, 2020SPYRAL DYSTAL Study to Evaluate the Effects of RDN Using Fewer, Targeted Ablations to Achieve Meaningful Blood Pressure Reductions
DUBLIN, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it will begin enrollment in a pilot study evaluating the safety and efficacy of the Symplicity™ Spyral renal...
-
Jan 30, 2020Next Generation Technology Includes Features that Automatically Adjust to Patient Needs, and Offers Physicians Heart Failure Diagnostic Insights
DUBLIN, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE (Conformité Européenne) Mark for its Cobalt™ and Crome™ portfolio of implantable...